Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Bamadutide in Type 2 Diabetes Mellitus
NCT02973321Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of bamadutide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Sanofi. Primary endpoint: Change From Baseline in HbA1c at 26 weeks. Started Dec 2016; status: completed.
02
Drugs
bamadutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02973321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973321.